FIELD: chemistry.
SUBSTANCE: invention relates to a method for cleavage of a solid phase-bound polypeptide from the solid phase, wherein the method involves bringing the solid phase whereto the polypeptide is bound into contact with a composition consisting substantially of trifluoroacetic acid and 1,2-ethanediol at a temperature from 23 to 29°C, wherein the composition is brought into contact with the solid phase whereto the polypeptide is bound for a period of 3 to 5 hours, wherein the polypeptide is selected from GLP-1, analogues and derivatives thereof, exendin-3, analogues and derivatives thereof, and exendin-4, analogues and derivatives thereof.
EFFECT: method allows for an increase in the yield of the peptide.
10 cl, 20 dwg, 30 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
METHOD FOR PRODUCING PEPTIDES CONTAINING LIPOPHILICALLY MODIFIED LYSINE SIDE CHAIN | 2017 |
|
RU2755543C2 |
METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
SACCHARIDE CHAIN-POLYPEPTIDE COMPLEXES | 2014 |
|
RU2664539C2 |
PRODRUGS CONTAINING EXENDIN CONJUGATE-LINKER | 2011 |
|
RU2593774C2 |
PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
LIRAGLUTIDE SYNTHESIS | 2017 |
|
RU2766331C2 |
NEW POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION AGAINST HIV-INFECTION | 1994 |
|
RU2136696C1 |
GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
Authors
Dates
2022-05-11—Published
2019-04-10—Filed